How the TM-Flow System Enhances Chronic Disease Management: 3 Key Benefits

Effective TM-Flow chronic disease management begins with objective, quantifiable data. By incorporating autonomic and vascular testing into chronic care programs, physicians gain actionable metrics that improve treatment decisions, patient engagement, and documentation and reimbursement within chronic care management (CCM) programs.

Chronic disease management programs are the backbone of modern primary care and specialty practice. Conditions like diabetes, heart failure, COPD, and hypertension require ongoing monitoring and risk stratification. The TM-Flow System enhances these programs by providing objective, quantifiable autonomic and vascular data at each patient visit, allowing care teams to identify deterioration objectively and adjust treatment plans based on measurable physiological changes rather than subjective symptoms alone. For diabetic patients specifically, pairing risk stratification with a structured diabetic foot exam helps document neuropathy and vascular complications in patients who present with symptoms.

How TM-Flow Chronic Disease Management Improves Patient Outcomes

Many chronic disease management decisions rely on lab results that change slowly and patient-reported symptoms that can be unreliable. The TM-Flow System fills this gap with real-time autonomic and vascular measurements that reflect a patient’s current physiological state.

Heart rate variability (HRV) analysis documents shifts in sympathetic-parasympathetic balance in patients already under management for cardiac decompensation or diabetic autonomic neuropathy. These autonomic changes can be measured objectively over time, so care teams can see whether a documented problem is improving or worsening under the current treatment plan.

Ankle-Brachial Index (ABI) testing documents peripheral circulation changes in diabetic patients who present with documented symptoms or risk indications. Serial ABI measurements create a vascular trend line that documents disease progression or improvement more precisely than periodic physical exams.

Sudomotor function testing assesses small-fiber nerve function, which nerve conduction studies do not measure. For chronic disease patients with diabetes and documented neuropathic symptoms, this adds an objective measure to the clinical picture the physician is already managing.

Three Clinical Benefits for Chronic Care Programs

1. Objective Data for Treatment Decisions

Chronic disease management programs require documented evidence that treatment plans are working. The TM-Flow System provides quantifiable, reproducible measurements that show whether a patient’s autonomic and vascular health is improving, stable, or declining. This data transforms care plan reviews from subjective assessments into data-driven discussions.

For diabetes management, serial HRV readings track whether glycemic control improvements are translating into measurable autonomic recovery. For hypertension patients, arterial stiffness measurements document whether antihypertensive therapy is achieving vascular end-organ protection beyond blood pressure targets. For heart failure patients, autonomic balance metrics can add objective context to decompensation risk.

This objective documentation strengthens clinical decision-making and supports the medical-necessity record for ongoing management. Testing is appropriate when the patient has documented symptoms or risk indications, and the results inform clinical management.

2. Improved Patient Engagement and Adherence

Visual TM-Flow reports give patients a clear picture of their vascular and autonomic health over time. Color-coded trend data showing improvement or decline motivates medication adherence and lifestyle changes more effectively than abstract lab numbers. When patients can see a visual representation of how their walking program improved their ABI score or how medication compliance stabilized their HRV, they become active participants in their care.

For care coordinators managing chronic disease populations, the system provides structured, objective documentation that supports referral decisions, prior authorization requests, and quality measure reporting for value-based care contracts. Practices that want help standing up or running a care management program often bring in a partner such as Practice Management Consultancy’s care management implementation service. The visual reports also simplify patient education conversations. A 30-second review of a color-coded trend chart communicates more than a 10-minute discussion of lab values.

3. Enhanced Care Coordination Across Providers

Chronic disease patients frequently see multiple specialists: primary care, endocrinology, cardiology, nephrology, and wound care. TM-Flow results provide a common physiological baseline that all providers can reference, reducing duplicative testing and ensuring consistent risk assessment across the care team.

When a primary care physician identifies declining HRV and worsening ABI in a diabetic patient, the referral to cardiology or vascular surgery arrives with objective data that accelerates specialist evaluation. This coordinated approach reduces the referral-to-treatment timeline and helps prevent the gaps in care that lead to adverse events in chronic disease populations.

Coding and Documentation in Chronic Care Settings

TM-Flow testing is reported under established CPT codes (93923, 95921, 95923) when the studies are performed and documented. Practices running Chronic Care Management (CCM) programs under CPT 99490 and 99491 also need objective clinical data in the record, and autonomic and vascular measurements can contribute to that documentation.

Coverage is determined by Medicare under the applicable LCDs when the testing is medically necessary and documented. Confirm code applicability and coverage with your Medicare Administrative Contractor before adding the testing to a chronic care workflow.

Which Chronic Disease Patients Warrant Testing?

Testing is appropriate when a patient has documented symptoms or risk indications that make the study medically necessary. Situations where physicians most often document that need include:

• Diabetic patients with documented neuropathic or vascular symptoms: objective measures add to the symptom record
• Heart failure patients (NYHA Class II-III): autonomic imbalance is part of the clinical picture being managed
• Hypertensive patients on multi-drug regimens: arterial stiffness measures end-organ protection
• COPD patients with cardiovascular comorbidities: autonomic dysfunction accelerates disease progression
• Chronic kidney disease patients: peripheral vascular compromise affects dialysis access planning

Most practices begin with their highest-risk chronic disease patients, testing when documented findings warrant it during follow-up visits, building clinical experience and documentation as they go.

Implementing TM-Flow in Your Chronic Care Program

The TM-Flow System is available through HealthWright Technologies. The CMAT Advantage package pairs the device with staff training, billing guidance, and ongoing support. Implementation typically involves identifying your chronic disease patient cohort, training one medical assistant on the 60-minute certification protocol, and integrating the testing workflow into existing visit templates.

For practices with established endocrinology or PAD testing workflows, adding TM-Flow to chronic disease management visits requires minimal additional chair time. The automated 7 to 10 minute protocol runs while the physician reviews other documentation, and results are available for discussion during the encounter.

CPT codes are provided for informational purposes only and do not guarantee reimbursement. Verify code applicability and coverage with your Medicare Administrative Contractor and your billing department before submitting claims. CPT® is a registered trademark of the American Medical Association.

Ready to get started? Contact HealthWright Technologies to learn how the TM-Flow System can enhance your chronic disease management program, backed by our 60-day buyback: bill the CMAT Advantage tests correctly and compliantly, and if Medicare does not reimburse them, we buy the system back.

Frequently Asked Questions

How does TM-Flow improve chronic disease management programs?

TM-Flow provides objective, quantifiable autonomic and vascular measurements at each patient visit, allowing care teams to track physiological changes with objective measurements. Heart rate variability analysis documents autonomic shifts in patients already under management for cardiac or diabetic complications, and ABI testing documents peripheral circulation changes in patients with documented symptoms or risk indications.

What billing codes support TM-Flow in chronic care management?

TM-Flow testing is reported under CPT codes 93923, 95921, and 95923 when the studies are performed and documented. Practices running Chronic Care Management (CCM) programs under CPT 99490 and 99491 also need objective clinical data in the record. Coverage is determined by Medicare under the applicable LCDs, so confirm code applicability with your Medicare Administrative Contractor.

Which chronic diseases benefit most from TM-Flow testing?

Diabetes, heart failure, hypertension, COPD, and chronic kidney disease patients benefit most from TM-Flow testing because these conditions involve progressive autonomic and vascular dysfunction that can be measured and tracked with the system’s three-test protocol. Diabetic patients are tested most often, when they present with documented neuropathic or vascular symptoms.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and clinical decision-making.

Teams weighing their options can review how the TM-Flow and CMAT Advantage systems compare.